Results 31 to 40 of about 23,127 (334)

A single supplement of a standardised bilberry (Vaccinium myrtillus L.) extract (36 % wet weight anthocyanins) modifies glycaemic response in individuals with type 2 diabetes controlled by diet and lifestyle [PDF]

open access: yes, 2013
Peer reviewedPublisher ...
Bestwick, Charles   +6 more
core   +1 more source

Glutamate Acts as a Key Signal Linking Glucose Metabolism to Incretin/cAMP Action to Amplify Insulin Secretion

open access: yesCell Reports, 2014
Incretins, hormones released by the gut after meal ingestion, are essential for maintaining systemic glucose homeostasis by stimulating insulin secretion.
Ghupurjan Gheni   +21 more
doaj   +1 more source

A surgical model of short bowel syndrome induces a long-lasting increase in pancreatic beta-cell mass [PDF]

open access: yes, 2015
Several surgical techniques are used nowadays as a severe treatment for obesity and diabetes mellitus type 2. These techniques are aggressive due to drastic changes in the nutrient flow and non-reversible modifications on the digestive tube.
Aguilar Diosdado, Manuel   +6 more
core   +2 more sources

Structural changes in intestinal enteroendocrine cells after ileal interposition in normal rats [PDF]

open access: yes, 2011
INTRODUCTION: No therapeutic approach has significantly impacted the progression of diabetes. As early improvement of glicaemic control is observed after bariatric surgeries, there is currently a search for surgical procedures that can promote euglycemia
Aparecida Hirata   +16 more
core   +2 more sources

NDRG1 Activity in Fat Depots Is Associated With Type 2 Diabetes and Impaired Incretin Profile in Patients With Morbid Obesity

open access: yesFrontiers in Endocrinology, 2021
ObjectiveWe aimed to investigate insulin-, mTOR- and SGK1-dependent signaling basal states in morbidly obese patients’ fat. We analyzed the correlation between the signaling activity, carbohydrate metabolism, and incretin profiles of patients.MethodsThe ...
Iurii Stafeev   +21 more
doaj   +1 more source

Incretins and microRNAs: interactions and physiological relevance.

open access: yesPharmacological Research, 2020
MicroRNAs (miRNA) are one class of the small regulatory RNAs that can impact the expression of numerous genes including incretin hormones and their G protein-coupled receptors.
Shabnam Radbakhsh   +3 more
semanticscholar   +1 more source

Obesity without diabetes: the role of hormonal regulation

open access: yesТерапевтический архив, 2020
Aim.Obese patients without diabetes present an interesting phenotype to explore protective mechanisms against type 2 diabetes (T2D) development. In our study we looked for specific hormonal features of obese patients without T2D. Materials and methods.
E. A. Shestakova   +5 more
doaj   +1 more source

Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders

open access: yesFrontiers in Pharmacology, 2022
GPR40 is a class A G-protein coupled receptor (GPCR) mainly expressed in pancreas, intestine, and brain. Its endogenous ligand is long-chain fatty acids, which activate GPR40 after meal ingestion to induce secretion of incretins in the gut, including GLP-
Hong-Ping Guan, Yusheng Xiong
doaj   +1 more source

Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis [PDF]

open access: yes, 2015
Aims/Introduction: According to some authors, in type 2 diabetes there is a reduced postprandial action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Amato, M.   +4 more
core   +1 more source

Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies

open access: yesМедицинский совет, 2020
The article discusses the potential opportunities for impact of antidiabetic drugs from the group of glucagon-like peptide-1 (GLP- 1) receptor agonists on the risks of development and progression of cardiovascular complications in patients with type 2 ...
Yu. Sh. Khalimov, V. G. Kuzmich
doaj   +1 more source

Home - About - Disclaimer - Privacy